Gold bars to be exempt from tariffs, White House clarifies
Investing.com -- Regeneron Pharmaceuticals Inc. reported fourth-quarter earnings and revenue that exceeded analyst expectations, sending shares up 2% in early trading.
The biotechnology company posted adjusted earnings per share of $12.07, surpassing the consensus estimate of $11.27. Revenue rose 10% year-over-year to $3.79 billion, beating analyst projections of $3.76 billion.
Regeneron (NASDAQ:REGN)’s flagship eye drug franchise, consisting of EYLEA HD and EYLEA, saw U.S. net sales increase 2% to $1.50 billion in Q4 compared to the same period last year. EYLEA HD, approved in August 2023, contributed $305 million to the total.
Dupixent, developed in partnership with Sanofi (NASDAQ:SNY), continued its strong growth trajectory. Global net sales of the immunology drug jumped 15% to $3.70 billion in Q4.
"Regeneron’s financial and commercial strength allows for continued investment in our industry-leading R&D pipeline, while simultaneously returning capital to our shareholders through our newly initiated dividend program and increased share repurchase capacity," said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and CEO of Regeneron.
The company announced it will initiate a quarterly cash dividend of $0.88 per share, payable on March 20, 2025. Regeneron’s board also authorized an additional $3 billion share repurchase program, bringing the total current capacity to approximately $4.5 billion.
For full-year 2025, Regeneron expects non-GAAP R&D expenses of $5.0-$5.2 billion and non-GAAP SG&A expenses of $2.55-$2.7 billion.